New and emerging developments in extensive-stage small cell lung cancer therapeuticsMamta Parikh, Primo N. Lara, Jonathan W. Riess|Current Opinion in Oncology|2016Cited by 24
A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i> <i>-</i> Altered Advanced Solid Tumor Malignancies (NCI 10170)Edward Maldonado, Rahul Aggarwal, W. Kimryn Rathmell et al.|Cancer Research Communications|2024Cited by 14
AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study.Nicholas G. Cost, James I. Geller, Lindsay A. Renfro et al.|Journal of Clinical Oncology|2025Cited by 7
A phase 2 study of the WEE1 inhibitor AZD1775 in <i>SETD2</i>-deficient advanced solid tumor malignancies.Edward Maldonado, Rahul Aggarwal, W. Kimryn Rathmell et al.|Journal of Clinical Oncology|2023Cited by 3
Neoadjuvant niraparib in men with DNA repair gene deficient clinically localized prostate cancer: Clinical and molecular results from a phase 2 investigator-initiated trial.Marc Dall’Era, Primo N. Lara, Nicholas Mitsiades et al.|Journal of Clinical Oncology|2025Cited by 1